Clinical Trials

    Showing 1 - 8 of 8 Joseph Masdeu

    18F-MK-6240 Tau PET and Brain Inflammation in Alzheimer’s Disease

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Nilene Crisci

    Phone: 713.441.3771

    To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verifying ... Read more >

    Glutathione and Alzheimer's Disease

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Chimaoge Okafor

    Phone: 713.363.7729

    Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the... Read more >

    Glutathione in Mild Cognitive Impairment

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Chimaoge Onyechi

    Phone: 713.363.7729

    Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanism... Read more >

    Houston Alzheimer Disease Study

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Andrea Franco Pando

    Phone: 713.441.1150

    The purpose of this study is to clarify at the individual level what genes and changes in the body predispose people to Alzheimer’s disease or other dementias. We will measure changes in brain imaging, body fluids, and memory or thinking abilities. V... Read more >

    Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS)

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Jeffrey Ling

    Phone: 713.363.7753

    The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, bioma... Read more >

    NMDA Receptor in Psychosis: Specific Auto-Antibodies

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator:

    Phone:

    Schizophrenic and bipolar psychoses are chronic and disabling brain disorders that affect people of all backgrounds. It is thought that in the brain of people with schizophrenic psychosis there is a decreased amount of a receptor known as the N-acety... Read more >

    Ocrelizumab for Psychosis by Autoimmunity (OPA)

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Nilene Crisci

    Phone: 713.441.3771

    Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack ... Read more >

    Role of Brain Inflammation in Alzheimer’s Disease

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Nilene Crisci

    Phone: 713.441.3771

    The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is impor... Read more >